Life
Lilly's Foundayo pill cut sleep apnea events by nearly half in a yearlong trial. FDA filing comes by year-end
In people not using a breathing machine, Lilly's daily obesity pill cut breathing interruptions by 43.8% over 52 weeks, versus 6.3% on placebo. Lilly plans to ask the FDA to approve it for sleep apnea by the end of 2026.
November 9, 2026 · 2 min read
